We have long covered this portion of the bi-coastal US patent fights between Merck and Gilead — over the effects of some basic Merck Hep C sofosbivur patents — and the purported need for Gilead to license those patents, and pay a royalty to Kenilworth — in order to be able to sell Sovaldi® and Harvoni®, in the US.
The post trial briefing on how much of Gilead’s legal fees Merck will be ordred to pay has been stretched a bit — in an order just entered in San Jose, California — thus:
. . . .
Oct. 14, 2016| Oct. 28, 2016 | Gilead files opening brief regarding amount of fees award
Nov. 4, 2016| Nov. 18, 2016 | Merck files opposition brief regarding amount of fees award Nov. 18, 2016| Dec. 2, 2016 | Gilead files reply brief regarding amount of fees award. . . .
And. . . Go Cubs GO — close out the Giants!